Olverembatinib Added to NCCN Guidelines for CML : vimarsana.

Olverembatinib has been added to the NCCN's latest guidelines for the treatment of patients with chronic myeloid leukemia.

Related Keywords

China , Chinese , Ascentage Pharma , Dajun Yang , National Comprehensive Cancer Network , Practice Guidelines , Bcr Abl1 Tki , Olverembatinib , Chronic Myeloid Leukemia , Ncml ,